

ACKNOWLEDGEMENT TO REFEREES

© Springer International Publishing AG, part of Springer Nature 2017. This article is an open access publication

Dear Reader,

As we reach the final issue of *Drugs in R&D* for 2017, we wish to reflect on another successful year's achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content.

2017 was a successful year for *Drugs in R&D* with over 60 articles published.

The quality of articles published in the journal is also reflected in its most recent Scimago 2-year citations per document value of 2.139. The journal was also included this year in the Emerging Sources Citation Index from Clarivate Analytics. Other journals in the Adis Premier Journals Portfolio (<http://www.springer.com/gp/adis>) continue to prosper, and this year has seen the successful launch of *PharmacoEconomics - Open*, the newest journal in the portfolio. The journal has published a full volume of 30 articles in its first year, plus many more online first. Following in the steps of Adis' flagship subscription journal in the field, *PharmacoEconomics*, the new open-access journal focuses on cost and health outcomes associated with drugs, devices and other healthcare interventions.

We thank the authors who have contributed articles to *Drugs in R&D* over the course of 2017. The skill and dedication of all authors are critical to the continued publication of the journal. The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal's content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers for *Drugs in R&D* in the last 12 months:

*A. Abuhelwa*, Australia  
*A. Aghazadeh-Habashi*, Canada  
*E. Aguera*, USA  
*J. Algorta*, Spain  
*S. Allegra*, Italy  
*E. Andres*, France  
*M. Asselin-Labat*, Australia  
*M. Avent*, Australia  
*J. Bernstock*, UK  
*Z. Binkhathlan*, Saudi Arabia  
*J. Boissel*, France  
*G. Borasi*, UK  
*P. K. Borkowski*, Poland  
*A. Braddy*, USA  
*S. Chirumbolo*, Italy  
*C. Comacchio*, Italy  
*D. Crawford*, USA

*R. Crazzolara*, Austria  
*M. Gomes Davanço*, Brazil  
*A. Di Paolo*, Italy  
*L. Endrenyi*, Canada  
*C. Engelmann*, Germany  
*P. Fagiolino*, Uruguay  
*J. Gailer*, Canada  
*A. Gaweda*, USA  
*A. Gils*, Belgium  
*A. Giorgio*, Italy  
*R. Gonzalez*, Spain  
*F. Gozzo*, USA  
*T. Gratieri*, Brazil  
*Y. Higashi*, Japan  
*Y. Hiramine*, Japan  
*U. Holtick*, Germany  
*J. Hughes*, Australia

- K. Itoh*, Japan  
*P. Janssen*, The Netherlands  
*S. Janssen*, France  
*M. Jones*, Ireland  
*A. Kamijo-Ikemori*, Japan  
*M. Georg Kees*, Germany  
*V. Kemmel*, France  
*M. V. Khvostov*, The Russian Federation  
*V. Kouranos*, UK  
*E. Kutoh*, Japan  
*L. Langman*, USA  
*A. Leichtle*, Switzerland  
*J. Li*, Canada  
*A. Ligresti*, Italy  
*J. Livezey*, USA  
*Y. Ting Ma*, UK  
*M. Macaluso*, USA  
*F. Malard*, France  
*B. Malhotra*, USA  
*N. Manickam*, India  
*R. Menon*, USA  
*F. Meyer*, Germany  
*E. Mogalian*, USA  
*H. Montazeri*, USA  
*J. Morita*, Japan  
*M. Muller*, USA  
*M. Nabissi*, Italy  
*H. Nakayama*, Japan  
*M. Narukawa*, Japan  
*T. Nava*, Switzerland  
*V. Nikolic*, Serbia  
*O. Osokogu*, The Netherlands  
*S. Ouwerkerk-Mahadevan*, Belgium  
*A. Pareek*, India  
*B. Patel*, India  
*H. Pelloux*, France  
*E. Pinter*, Hungary  
*B. Pohlmann-Eden*, Canada  
*E. Puris*, Finland  
*G. Rath*, India  
*C. Roger*, France  
*S. Roth*, Germany  
*J. Ruiz de Morales*, Spain  
*S. Sadiq*, USA  
*M. Safak*, USA  
*K. Saito*, Japan  
*A. Sallam*, Egypt  
*R. Salloum*, USA  
*D. Santini*, Italy  
*J. Santos*, Spain  
*H. Schellekens*, The Netherlands  
*S. A. Schug*, Australia  
*F. Shaerzadeh*, Islamic Republic of Iran  
*A. Shawky Elserafy*, Egypt  
*J. Skupien*, USA  
*M. Yearsley Smith*, USA  
*C. F. Stewart*, USA  
*N. Sugano*, Japan  
*W. Sumner*, USA  
*A. Svennebring*, Sweden  
*P. Szabó-Révész*, Hungary  
*R. H. Takahashi*, USA  
*D. Taylor*, USA  
*J. Thorsteinsdottir*, Germany  
*S. Trifilio*, USA  
*N. Vande Castele*, USA  
*M. Wadelius*, Sweden  
*D. Wahl*, USA  
*J. H. Watanabe*, USA  
*J. Whritenour*, USA  
*Z. Ye*, USA  
*Y. Zhang*, USA

In addition, we would like to thank the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:

- G. An*, University of Iowa, Iowa, IA, USA  
*R.K. Campbell*, Washington State University, Pullman, WA, USA  
*D. Cattaneo*, Luigi Sacco University Hospital, Milan, Italy  
*G. Cherala*, Eastern Virginia Medical School, Norfolk, VA, USA  
*Y.K. Gupta*, All India Institute of Medical Sciences, New Delhi, India  
*H.P. Hartung*, Heinrich-Heine University, Dusseldorf, Germany  
*C. Höcht*, University of Buenos Aires, Buenos Aires, Argentina  
*N.M. Idkaidek*, University of Petra, Amman, Jordan  
*F. Jamali*, University of Alberta, Edmonton, AB, Canada  
*T.K.L. Kiang*, The University of British Columbia, Vancouver, BC, Canada  
*M.J. McKeage*, University of Auckland, Auckland, New Zealand  
*P.J. Nathan*, Monash University, Melbourne, VIC, Australia  
*B.M. Patel*, Nirma University, Ahmedabad, India  
*S. Perez-Lloret*, Institute for Cardiology Research, National Research Council (ININCA-UBA-CONICET), Buenos Aires, Argentina  
*M. Pfister*, University of Basel, Basel, Switzerland  
*G. Remington*, University of Toronto, Toronto, ON, Canada  
*H. Schütz*, BEBAC Consulting, Vienna, Austria  
*M.H. Shishehbor*, Cleveland Clinic Cardiovascular Disease, Cleveland, OH, USA  
*L.P. Shulman*, Feinberg School of Medicine of Northwestern University, Chicago, IL, USA  
*L. Tóthfalusi*, Semmelweis University, Budapest, Hungary  
*R. Vats*, Hyderabad Campus, Hyderabad, India  
*J. Weiss*, University of Heidelberg, Heidelberg, Germany

We do hope that you have found the articles published throughout the year in *Drugs in R&D* to be interesting and informative. The editorial schedule for 2018 is well under way, and we are looking forward to bringing you many high-quality and authoritative articles over the coming year.

With best wishes, Anton van Rensburg

**Open Access** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.